The company pursues this mission through its own internal research and development and ongoing sponsored research and licensing agreements with a pediatric academic medical center.

In June 2016, Medgenics entered into a collaboration with Kyowa Hakko Kirin for the development and commercialization of the Japanese company's first-in-class biologic for severe pediatric onset inflammatory bowel disease.